ReviewCell death discovery2026
Research advances of copper homeostasis and cuproptosis in orthopedic diseases.
Review in Cell death discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Copper is an essential trace element that plays a significant role in human physiological functions. However, abnormal accumulation of copper can trigger a programmed cell death mechanism known as cuproptosis, which has a significant pathological impact, especially in orthopedic diseases such as osteoarthritis (OA), rheumatoid arthritis (RA), osteosarcoma (OS), and osteoporosis (OP). Cuproptosis not only causes damage to cell membranes, proteins and DNA through oxidative stress mechanisms, but also triggers apoptosis by disrupting mitochondrial function, thereby further exacerbating the structural damage of bone and cartilage tissues. The cuproptosis-related genes (CRGs) exhibit unique biological functions in regulating these pathological processes, and thus become potential diagnostic markers and therapeutic targets. In this regard, we have proposed an innovative therapeutic approach that utilizes the water gel sustained-release technology to load natural antioxidants. The aim is to achieve multi-dimensional targeted cuproptosis through improving drug delivery. Furthermore, natural substances such as sage extract, cinnamon and probiotics have demonstrated the potential for potent antioxidant and anti-inflammatory effects, providing a foundation for future therapeutic strategies. A key challenge for these strategies will be to precisely modulate copper levels to induce therapeutic cuproptosis in pathological cells (e.g., in osteosarcoma or hyperactive osteoclasts) while preserving the essential physiological functions of copper in normal bone and cartilage remodeling. Exosomal miRNAs provide a new perspective for intervening in the pathologies caused by copper through regulating copper homeostasis and related signaling pathways. Future research will focus on optimizing the combination application of these natural drugs, exploring the potential of different copper chelators and pioneering the design of innovative biomaterials, in order to achieve better control of cuproptosis and innovative progress in the treatment of orthopedic diseases.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.